Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García JM, Llombart-Cussac A, G Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MÁ, Soberino J, Malfettone A, Schmid P, Cortés J. Pérez-García JM, et al. Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. Eur J Cancer. 2021. PMID: 33794440 Clinical Trial.
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E. Colomer R, et al. Cancer. 2007 Nov 15;110(10):2178-85. doi: 10.1002/cncr.23043. Cancer. 2007. PMID: 17926331 Free article.
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M. Llombart-Cussac A, et al. Cancer. 2012 Jan 1;118(1):241-7. doi: 10.1002/cncr.26299. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717449 Free article. Clinical Trial.
Progress against solid tumors in danger: the metastatic breast cancer example.
Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Cortés J, et al. J Clin Oncol. 2012 Oct 1;30(28):3444-7. doi: 10.1200/JCO.2012.41.9580. Epub 2012 Aug 27. J Clin Oncol. 2012. PMID: 22927522 Free PMC article. No abstract available.
Reply to A. Ocana et al.
Cortés J, Llombart-Cussac A, Calvo E. Cortés J, et al. J Clin Oncol. 2013 Mar 20;31(9):1253-4. doi: 10.1200/JCO.2012.47.8271. J Clin Oncol. 2013. PMID: 23616989 No abstract available.
129 results